Richard A. Heyman
Director at Enliven Therapeutics, Inc. (ELVN); Director at Oric Pharmaceuticals, Inc. (ORIC)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $741K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Oct 2SEC | ORICOric Pharmaceuticals, Inc. | Sell Plan | 3,50038,300 held (−8%) | $12.91 | $45K | -7.2% |
| Oct 2SEC | ORICOric Pharmaceuticals, Inc. | Sell Plan | 3,200203,472 held (−2%) | $12.91 | $41K | -7.2% |
| Jul 28SEC | ORICOric Pharmaceuticals, Inc. | Sell Plan | 7,00038,300 held (−15%) | $12.02 | $84K | -0.2% |
| Jul 28SEC | ORICOric Pharmaceuticals, Inc. | Sell Plan | 6,100206,672 held (−3%) | $12.02 | $73K | -0.2% |
| Jul 8SEC | ORICOric Pharmaceuticals, Inc. | Sell Plan | 300212,772 held (−0%) | $12.00 | $4K | -0.1% |
| Feb 19SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 1,23022,647 held (−5%) | $26.18 | $32K | +56.5% |
| Jan 22SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 51224,595 held (−2%) | $26.46 | $14K | +54.9% |
| Jan 22SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 71823,877 held (−3%) | $26.96 | $19K | +52.0% |
| Jan 20SEC | ORICOric Pharmaceuticals, Inc. | Sell Plan | 3,50041,800 held (−8%) | $12.00 | $42K | -0.1% |
| Jan 20SEC | ORICOric Pharmaceuticals, Inc. | Sell Plan | 3,200213,072 held (−1%) | $12.00 | $38K | -0.1% |
| Jan 12SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 1,62025,545 held (−6%) | $25.00 | $40K | +63.9% |
| Jan 12SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 8,01529,392 held (−21%) | $25.04 | $201K | +63.7% |
| Jan 12SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 4,28525,107 held (−15%) | $25.00 | $107K | +63.9% |
- Sell
Director Richard A. Heyman sold $45K of ORIC at $12.91 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Richard A. Heyman sold $41K of ORIC at $12.91 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Richard A. Heyman sold $84K of ORIC at $12.02 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Richard A. Heyman sold $73K of ORIC at $12.02 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Richard A. Heyman sold $4K of ORIC at $12.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Richard A. Heyman sold $32K of ELVN at $26.18 — pre-scheduled 10b5-1 plan sale.